News Moderna agrees $950m settlement of mRNA jab litigation Moderna's settlement of patent litigation with Arbutus and Genevant over technology used in its Spikevax COVID vaccine could reach up to $2.25bn.
News Zydus follows Lupin with Myrbetriq settlement deal Zydus has joined Lupin in agreeing to settle patent litigation with Astellas on its generic of big-selling overactive bladder drug Myrbetriq.
News Lupin settles Myrbetriq patent spat with Astellas for $90m Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement.
News Bayer's Monsanto sues mRNA COVID-19 vaccine makers Lawsuits filed by Bayer in the US are seeking damages and royalties on sales of COVID-19 shots sold by Pfizer/BioNTech, Moderna, and J&J.
News China delivers a win for Novo Nordisk on semaglutide IP Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which backed the validity of its patent on GLP-1 agonist semaglutide.
News Setback for MSD as German court blocks Keytruda SC launch A court in Germany has granted an injunction that will prevent MSD from distributing the new, subcutaneous version of its cancer drug Keytruda.
R&D LSX2026: On a therapeutic vision for ocular disease, with Al... Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.